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Abstract
Aims/hypothesis The thiazolidinedione (TZD) rosiglitazone
is a peroxisome proliferator-activated receptor-γ agonist
that induces adipocyte differentiation and, hence, lipid
accumulation. This is in apparent contrast to the long-term
glucose-lowering, insulin-sensitising effect of rosiglitazone.
We tested whether the action of rosiglitazone involves
specific effects on mature adipocytes, which are different
from those on preadipocytes.
Materials and methods Differentiated mature 3T3-L1 adipo-
cytes were used as an in vitro model. Transcriptomics, proteo-
mics and assays of metabolism were applied to assess the effect
of rosiglitazone in different insulin and glucose conditions.
Results Rosiglitazone does not induce an increase, but
rather a decrease in the lipid content of mature adipocytes.
Analysis of transcriptome data, confirmed by quantitative
RT-PCR and measurements of lipolysis, indicates that an
altered energy metabolism may underlie this change. The
pathway analysis shows a consistent picture dominated by
lipid catabolism. In addition, we confirmed at both mRNA
level and protein level that rosiglitazone represses adipo-
kine expression and production, except for genes encoding
adiponectin and apolipoprotein E. Moreover, transcriptome
changes indicate that a general repression of genes
encoding secreted proteins occurs.
Conclusions/interpretation Our findings suggest that the
change of adiposity as seen in vivo reflects a shift in
balance between the different effects of TZDs on preadi-
pocytes and on mature adipocytes, while the changes in
circulating adipokine levels primarily result from an effect
on mature adipocytes.
Keywords Adipokine . Adipose tissue . Energy
metabolism . Lipogenesis . Lipolysis . Mature adipocytes .
Microarray . Secretion . Thiazolidinediones
Abbreviations
ADFP adipocyte differentiation-related protein
APOE apolipoprotein E
CAV1 caveolin 1
1D one-dimensional
2D two-dimensional
FASN fatty acid synthase
IG high glucose and insulin condition
PPAR peroxisome proliferator-activated receptor
PPARG peroxisome proliferator-activated receptor-γ
PPRE PPAR-responsive element
Q-PCR quantitative real time RT- PCR
Rosi rosiglitazone with low (4.5 mmol/l) glucose
and (fetal calf serum level) insulin
RosiIG rosiglitazone with high (15.75 mmol/l)
glucose and 1 μmol/l insulin
RPS15 ribosomal protein S15
SCD1 stearoyl-coenzyme A desaturase 1
TCA cycle citric acid cycle
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Introduction
Rosiglitazone (BRL-49653), a thiazolidinedione (TZD)
drug, is used in the treatment of type 2 diabetes mellitus
[1]. It has been proposed that the glucose-lowering action
of TZDs is mainly mediated by activating peroxisome
proliferator-activated receptor (PPAR)-γ (PPARG) [2, 3].
PPARG is most abundantly produced in adipose tissue,
suggesting that this is the primary site of action of TZDs
[4]. Proposed mechanisms underlying the adipocyte-medi-
ated glucose-lowering action of TZDs are the trapping of
fatty acids inside adipocytes and away from muscle, the so-
called ‘fatty acid steal’ hypothesis and the altering
adipokine release [1].
PPARG is a critical transcription factor in adipogenesis
[5]. Its production increases strongly during adipocyte
differentiation [6]. By activating PPARG, rosiglitazone
promotes adipocyte differentiation in vitro [7, 8]. An
increase in the number of small adipocytes and fat mass
by TZDs in both animal models and human subjects,
suggests that adipocyte differentiation also occurs in vivo
[9, 10]. Compared with preadipocytes, adipocytes have a
much higher capacity for fatty acid uptake and lipid
storage and are potentially more insulin-sensitive due to
higher numbers of glucose transporters and insulin
receptors [6]. By increasing the number of adipocytes,
TZDs can lower circulating NEFA and improve lipid
exposure of peripheral tissues, thus improving whole-body
insulin sensitivity [1].
This hypothesis is clearly attractive, but other effects of
TZDs may occur. It has been pointed out that the increased
number of small adipocytes caused by TZD treatment is not
only a result of the appearance of new adipocytes, but also
due to the shrinkage and/or disappearance of existing
mature adipocytes [10]. TZD-induced body weight gain in
vivo is used as a marker of increased adiposity. However,
there is evidence that this may also be due to fluid retention
[11]. In fact, the fat mass may be unaffected or even
decreased. In ob/ob mouse, whole body weight was
increased, but the fat pad weight was not changed after
rosiglitazone treatment [12]. In type 2 diabetes patients, the
visceral fat area was found to be decreased [13]. ‘Fatty acid
steal’ therefore is not just a matter of increased lipid
storage.
The maturation of adipocytes is positively correlated
with the production of adipokines. Several of these
profoundly influence insulin sensitivity and glucose metab-
olism, e.g. leptin, adiponectin and resistin [14]. However, it
has been observed that TZDs decrease the circulating level
of individual adipokines such as leptin [15], resistin [16]
and plasminogen activator inhibitor-1 [17], and also of
cytokines [18]. A decreased production of these adipokines
by TZDs seems to conflict with the adipogenic properties of
these drugs.
The above discrepancy could be due to different effects
on preadipocytes and mature adipocytes in adipose tissue. It
is clear that TZDs stimulate preadipocytes into the process
of differentiation. However, their effect on mature adipo-
cytes is less clear. In vivo studies do not allow us to
distinguish between the effects on these two cell types.
Therefore, to study the effects of TZDs on mature
adipocytes, we used in vitro differentiated mature 3T3-L1
adipocytes. In addition to the assessment of lipid accumu-
lation and adipokine secretion, we used transcriptomics to
obtain insight into the effects of rosiglitazone. Although
high insulin and high glucose levels mimic the situation in
vivo when rosiglitazone is administered, we also included
low insulin and low glucose levels for comparison.
Materials and methods
Cell culture and sample preparation Murine 3T3-L1
fibroblasts (CL-173; American Type Culture Collection,
Manassas, VA, US) were cultured and differentiated to
adipocytes in vitro as described [19]. On day 8, differen-
tiated cells, grown in DMEM/F-12 (1:1) supplemented with
10% fetal calf serum (Perbio Science, Erembodegem,
Belgium), were treated with 0.5 μmol/l rosiglitazone
maleate (GlaxoSmithKline, Worthing, UK) with low
(4.5 mmol/l) glucose and (fetal calf serum level) insulin
(Rosi), or with high (15.75 mmol/l) glucose and 1 μmol/
l insulin (RosiIG). In parallel, control cells were cultured in
the same medium with low (basal) or high glucose and
insulin (IG). Each condition was created in quadruplicate.
On day 10, two replications were collected separately for
total RNA isolation using Trizol as described [19]. Cells of
the other two replications were washed and incubated with
the corresponding serum-free medium, supplemented with
2.2 mg/l transferrin and 10.6 nmol/l sodium selenite for 6 h.
The number of cells was counted and culture medium
proteins were collected as described [20]. The duplicated
protein samples were pooled for later analysis. Three
independent experiments were performed.
Oil red O staining An optimised Oil Red O staining
method [21] was adapted for 3T3-L1 adipocytes cultured
in a six-well plate. We added an additional quick wash with
70% ethanol after fixing and washing with water. After
staining and washing, the neutral lipid-bound pigment was
dissolved in DMSO and absorbance at 540 nm was
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measured. The staining for 3T3-L1 preadipocytes was used
as background to correct for unspecific binding. The
obtained absorbance values were further corrected for cell
numbers measured in replicated wells. Five independent
experiments were performed in duplicate, but in the first
two experiments Basal and Rosi conditions were not
measured.
Glycerol assay The culture media of cells that had been
treated for 48 h were collected per condition, frozen in
liquid N2, then stored at −80°C until analysis. The
concentration of glycerol in the medium was measured by
a quantitative enzymatic assay kit (Sigma, St Louis, MO,
USA), according to the manufacturer’s instructions. The
concentrations were corrected for cell numbers measured in
replicated wells in parallel.
Microarray The mouse 10K_A oligo set (MWG, Ebersberg,
Germany) and additional oligonucleotides of genes encoding
secretory proteins and proteins involved in energy metabo-
lism were printed in-house and further annotated as
described [19]. Five total RNA samples of three indepen-
dent experiments per condition were used for hybridisation
against reference RNA, also as described [19].
Microarray data analysis The data were analysed as
described [19]. Briefly, spots with an average intensity,
over all arrays, of lower than twofold above average
background were removed from further analysis, then the
intensities of the remaining 4,019 spots were normalised
against reference. Fold-change calculations, Student’s t tests
and correlation test (Pearson) were performed in Excel
(Microsoft). Fold-change equals ratio in the case of increase
and equals −1/ratio in the case of decrease. Cut-off criteria
for differential expression was set at fold-change >1.3 and
p<0.05. For genes with replicated spots, the average value
of individual spots was used.
Data were further analysed using Ingenuity Pathways
Analysis (Ingenuity Systems, http://www.ingenuity.com).
The program recognised 4,005 of 4,019 spot entries, and
thus 3,718 genes. Differentially expressed genes that
associated with a canonical pathway in the Ingenuity
Pathways Knowledge Base were considered for evaluation.
The significance of the association between the data set and
the canonical pathway was measured in two ways: (1) a
ratio of the number of genes from the data set that map to
the pathway divided by the total number of genes that map
to the canonical pathway is displayed; (2) Fischer’s exact
test was used to calculate a p value determining the
probability that the association between the genes in the
dataset and the canonical pathway is explained by chance
alone. A pathway with a significance <0.05 was taken as
significantly regulated.
Quantitative real-time RT-PCR All six total RNA samples
per treatment were used for quantitative real-time RT-PCR
(Q-PCR) of 22 genes (primer information in Electronic
supplementary material [ESM] Table 1). Q-PCR was
performed as described [19]. Ribosomal protein S15
(Rps15) mRNA was used as reference.
One- and two-dimensional gel electrophoresis Protein
samples were analysed by one-dimensional (1D) and two-
dimensional (2D) gel electrophoresis, corrected for cell
numbers, as described [19]. Brefeldin-A-treated adipocyte
medium protein sample [20] was loaded on the same 1D
gel, to verify protein secretion. Differentially expressed
secreted protein bands were excised and identified by
matrix-assisted laser desorption ionisation-time of flight
mass spectrometry [22].
Western blotting The secretion level of adiponectin was
analysed by 1D western blotting as described [20].
Results
Effect of rosiglitazone on the lipid content of mature
adipocytes To assess the effect of rosiglitazone on lipid
accumulation in mature adipocytes, we measured the lipid
content of differentiated 3T3-L1 adipocytes. Visual inspec-
tion by microscopy showed no change in morphology and
fat cell percentage in the population of 3T3-L1 adipocytes
after 2 days of treatment with RosiIG or Rosi (0.5 μmol/
l rosiglitazone at either high or low insulin/glucose levels,
respectively), as compared with untreated adipocytes.
Nevertheless, the lipid content, as detected by Oil Red O
staining, was 10% lower (p<0.001, n=5) in RosiIG-treated
cells, while no difference was observed in Rosi-treated cells
(Fig. 1).
Effect of rosiglitazone on gene expression To reveal the
possible mechanisms for the decreased lipid content of
rosiglitazone-treated 3T3-L1 adipocytes, we used DNA
microarray to profile the gene expression. The complete
analysis set was imported into Ingenuity PathwayAnalysis for
canonical pathway analysis. The significantly changed path-
ways were involved in metabolism, but not in signalling, such
as PPAR signalling or insulin receptor signalling (Fig. 2). The
expression of Pparg itself was downregulated 1.8- and 2.2-
fold (p<0.005) by Rosi and RosiIG treatment, respectively.
Notably, pathways related to energy metabolism were among
those that were most changed. Taking the high redundancy
among these pathways in the Ingenuity database into
account, we checked the individual pathways for redundan-
cy. This showed that oxidative phosphorylation, fatty acid
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Table 1 Key enzymes of metabolism pathways regulated by rosiglitazone
Pathway Change Gene
symbol
Gene
ID
Name Rosi/Basal RosiIG/IG
Fold-
change
p
value
Fold-
change
p
value
TCA cycle Up Idh3a 67834 Isocitrate dehydrogenase 3 (NAD+) alpha 2.53 0.000 2.55 0.000
Cs 12974 Citrate synthase 1.95 0.000 1.47 0.000
Oxidative
phosphorylation
Up Ndufa5 68202 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
1.72 0.009 1.20 0.235
Sdhd 66925 Succinate dehydrogenase complex, subunit D 1.83 0.001 1.51 0.039
Uqcrc1 22273 Ubiquinol-cytochrome c reductase core protein I 1.47 0.007 1.33 0.017
Cox7a1 12865 Cytochrome c oxidase subunit VIIa polypeptide 1 1.78 0.002 1.55 0.003
Atp5h 71679 ATP synthase, H+ transporting, mitochondrial
F0 complex, subunit d
1.71 0.006 1.49 0.005
Fatty acid uptake
and transport
Up Cd36 12491 CD36 antigen, fatty acid translocase 2.54 0.000 2.27 0.006
Fabp4 11770 Fatty acid bind protein 4, adipocyte 1.64 0.088 1.57 0.142
Fatty acid
activation
Up Acsl1 14081 Acyl-CoA synthetase long-chain family member 1 2.50 0.000 1.97 0.000
Fatty acid beta
oxidation
Up Crat 12908 Carnitine acetyltransferase 1.45 0.006 1.47 0.007
Slc25a20 57279 Solute carrier family 25 (mitochondrial carnitine/
acylcarnitine translocase), member 20
1.63 0.003 1.22 0.092
Acox1 11430 Acyl-coenzyme A oxidase 1, palmitoyl 2.70 0.000 2.54 0.000
Acaa1 113868 Acetyl-coenzyme A acyltransferase 1 (peroxisomal) 1.67 0.002 1.29 0.017
Acaa2 52538 Acetyl-coenzyme A acyltransferase 2
(mitochondrial)
2.70 0.000 1.94 0.000
Fatty acid
synthesis
Down Fasn 14104 Fatty acid synthase −1.52 0.000 −1.55 0.001
Scd1 20249 Stearoyl-CoA desaturase 1 −3.65 0,000 −4.31 0.000
Triacylglycerol
synthesis
Down Ppap2b 67916 Phosphatidic acid phosphatase type 2B −1.38 0.001 −1.48 0.000
Dgat2 67800 Diacylglycerol O-acyltransferase 2 −1.31 0.003 −1.37 0.006
Lipid droplet
formation
Up/down Adfp 11520 Adipose differentiation related protein 5.97 0.000 6.60 0.000
Cav1 12389 Caveolin, caveolae protein 1 −2.20 0.000 −2.30 0.001
Glycerolipid lysis Up Pnpla2 66853 Patatin-like phospholipase domain
containing 2
1.52 0.006 1.67 0.007
Glycerol metabolism Up Gk 14933 Glycerol kinase 1.86 0.007 1.88 0.003
Gpd1 14555 Glycerol-3-phosphate dehydrogenase 1 (soluble) 2.07 0.009 1.68 0.032
Energy expenditure Up Ucp2 22228 Uncoupling protein 2 (mitochondrial,
proton carrier)
1.78 0.001 1.50 0.003
Glutathione
metabolism
Up/down Mgst3 66447 Microsomal glutathione S-transferase 3 2.11 0.001 1.88 0.001
Gsta4 14860 Glutathione S-transferase A4 1.36 0.046 −1.01 0.924
Gstm1 14862 Glutathione S-transferase M1 −1.88 0.000 −2.01 0.010
Gstt1 14871 Glutathione S-transferase theta 1 −1.38 0.060 −1.51 0.044
Gstz1 14874 Glutathione transferase zeta 1 −1.44 0.001 −1.57 0.015
Prostaglandin
metabolism
Up/down Cbr3 109857 Carbonyl reductase 3 3.04 0.000 3.96 0.000
Ptges2 96979 Prostaglandin E synthase 2 1.45 0.012 1.61 0.000
Ptgis 19223 Prostaglandin I2 (prostacyclin) synthase −1.71 0.002 −1.41 0.004
Steroids
metabolism
Up/down Hsd17b7 15490 Hydroxysteroid 17-beta dehydrogenase 7 1.63 0.003 1.73 0.002
Nsdhl 18194 NAD(P) dependent steroid dehydrogenase-like 1.51 0.039 1.37 0.017
Hsd11b1 15483 Hydroxysteroid 11-beta dehydrogenase 1 −2.73 0.001 −2.05 0.004
Glyconeogenesis Up Fbp2 14120 Fructose-1,6-bisphosphatase 2 2.92 0.003 2.82 0.014
Glycogen synthesis Up Gyg 27357 Glycogenin 1.52 0.001 1.34 0.008
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metabolism, glycolysis and gluconeogenesis, the pentose
phosphate pathway, the citric acid (TCA) cycle, glycerolipid
metabolism, glutathione metabolism, steroid (androgen,
oestrogen and C21 steroids) metabolism and prostaglandin
metabolism are independent pathways, while for the others it
cannot be ruled out that they were identified as significant
just because they contain genes overlapping with other
pathways.
For these independently regulated pathways, we deter-
mined the direction of change by examining the individual
genes in the pathways. The regulation of gene expression of
rate-limiting or otherwise representative enzymes is pre-
sented in Table 1. High insulin/glucose attenuated the effect
of rosiglitazone on some genes of complex I and II of the
electron transport chain. However, high insulin/glucose
treatment itself did not induce a change in the expression
of these genes from the basal state. In general, rosiglitazone
produced dominant effects, as indicated by the Pearson
product moment correlation coefficient of 0.875 for the fold
changes of the complete analysis set of Rosi/Basal and
RosiIG/IG. The changes in the pathways indicate that
rosiglitazone enhanced both energy metabolism at the TCA
cycle and oxidative phosphorylation. The generated energy
may be dispensed with the help of upregulated uncoupling
protein 2 (Ucp2). Enhanced energy metabolism is mainly
supported by upregulation of the pathways involved in
uptake and activation of fatty acids and in beta-oxidation in
both mitochondria and peroxisomes. In contrast, de novo
fatty acid synthesis was downregulated, as indicated by
fatty acid synthase (Fasn) and stearoyl-coenzyme A
desaturase 1 (Scd1). The downregulation of triacylglycerol
synthesis enzymes and upregulation of adipocyte lipase
(also known as patatin-like phospholipase domain contain-
ing 2) together imply a decreased lipogenesis in mature
adipocytes (Table 1).
Accompanying fatty acid catabolism, glycerol activation
by glycerol kinase and oxidation by glycerol phosphate
dehydrogenase to dihydroxyacetone phosphate were upregu-
lated, feeding glycolysis and gluconeogenesis. The enzymes
catalysing glycolysis/gluconeogenesis were all upregulated,
possibly in favour of gluconeogenesis. In addition, the
upregulation of glycogenin, a gene priming glycogen
synthesis, implies an increase of glycogen synthesis.
Most genes in the amino acid metabolism pathways that
were regulated also participate in fatty acid metabolism or
in glycolysis. Therefore, we did not take amino acid
metabolism pathways as independent rosiglitazone-regulat-
ed pathways. However, two key enzymes that catalyse the
catabolism of leucine (Table 1) were downregulated. This
implies that rosiglitazone saves amino acids from being
used as fuel in energy metabolism.
Table 1 (continued)
Pathway Change Gene
symbol
Gene
ID
Name Rosi/Basal RosiIG/IG
Fold-
change
p
value
Fold-
change
p
value
Pyruvate
metabolism
Up Pdha1 18597 Pyruvate dehydrogenase E1 alpha 1 1.38 0.001 1.33 0.001
Pdhb 68263 Pyruvate dehydrogenase (lipoamide) beta 1.59 0.005 1.61 0.004
Pentose phosphate Up H6pd 100198 Hexose-6-phosphate dehydrogenase (glucose
1-dehydrogenase)
1.60 0.000 1.47 0.001
Taldo1 21531 Transaldolase 1 1.57 0.001 1.33 0.036
Leu catabolism Down Ivd 56357 Isovaleryl coenzyme A dehydrogenase −1.42 0.004 −1.72 0.000
Mccc1 72039 Methylcrotonoyl-coenzyme A carboxylase 1
(alpha)
−1.26 0.026 −1.35 0.031
Mean value of microarray data (n=5)
Rosi/basal: the effect with low insulin/glucose; RosiIG/IG: the effect with high insulin/glucose
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Fig. 1 Oil Red O staining (ORO) for lipid content in 3T3-L1
adipocytes. Data are expressed as mean±SD. n=5 for high glucose and
insulin (control condition) (IG) and rosiglitazone with high insulin and
glucose condition (RosiIG); n=3 for basal and rosiglitazone with low
insulin and glucose condition (Rosi). Blank bars: absorbance, relative
value; filled bars: absorbance, relative value corrected for cell
numbers. ** p<0.01 compared with IG condition before cell number
correction (t test), *** p<0.001 compared with IG condition after cell
number correction (t test)
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Glutathione metabolism was significantly changed by
rosiglitazone treatment. Two glutathione S-transferases that
detoxify lipid peroxides, microsomal glutathione S-trans-
ferase 3 and glutathione S-transferase A4, were upregu-
lated, while other glutathione S-transferases were
downregulated by rosiglitazone. This is in line with the
upregulation of fatty acid oxidation by rosiglitazone.
Microsomal glutathione S-transferase 3 is involved not
only in glutathione metabolism, but also in eicosanoid
metabolism, which is also regulated by rosiglitazone. The
expression of genes encoding enzymes involved in prosta-
glandin metabolism implies that the conversion from
prostaglandin H2 to E2, F2 and D2 may be enhanced, while
conversion to I2 may be reduced.
Cholesterol biosynthesis and steroid hormone metabo-
lism were also affected by rosiglitazone. Expression of
some steroid dehydrogenases were upregulated, while
hydroxysteroid 11-beta dehydrogenase 1 was downregu-
lated (Table 1). The latter has been reported as one of the
beneficial effects of TZDs, leading to a decrease in the
stress hormone cortisol [23].
Effect of rosiglitazone on the expression of genes encoding
adipocyte-secreted proteins To assess whether protein
secretion by mature adipocytes is altered by rosiglitazone,
we checked genes encoding adipocyte-secreted proteins.
The list was based on literature [24–27] and our previous
work [20]. In total, 61 genes were present on the array. Il1b,
Il6, Il10 and leptin showed very low signals (less than
twofold of background) and were excluded from the
analysis. Among the remaining 57 genes, only apolipopro-
tein E (Apoe) was upregulated by Rosi treatment, and more
than 40% of the genes were significantly downregulated
with both Rosi and RosiIG treatment (Table 2).
Interestingly, the general downregulation of adipokines
was also observed for other genes encoding secreted
proteins. We used Gene Ontology to cluster the expressed
genes on the microarray into secreted protein encoding genes
and intracellular/unknown location protein-encoding genes
(additional gene expression information is available at www.
foodbioactives.nl). In the first cluster, more genes were
significantly downregulated (Fig. 3a and c). Of 477 genes,
24.9 and 25.8% were significantly downregulated, while
9.6 and 6.7% were upregulated by Rosi and RosiIG,
respectively. Of the upregulated genes, most encode multi-
location proteins, which can also reside in the nucleus,
mitochondria and/or membranes. If these genes are omitted
from the analysis, only seven genes were upregulated
(1.5%). In the cellular protein cluster, by contrast, the
majority of the regulated genes were upregulated (Fig. 3b
and d). Of 3,382 genes, 10.3 and 10.1% were significantly
upregulated, while 5.1 and 5.0% were downregulated by
Rosi and RosiIG treatment, respectively.
To complement array data, we used 2D and 1D gel
electrophoresis and western blotting to examine the effect
of rosiglitazone on secretion. With regard to complement
C3, a 30% reduction of secretion by Rosi or RosiIG
treatment was observed on the 1D gel (Fig. 4). This is less
than the change observed at the gene expression level. Nine
spots on the 2D gel were identified as adipsin. We assessed
the changes for individual spots, as well as for all spots in
total. In both cases, the decrease effected by rosiglitazone at
the gene expression level was similar to the decrease found
at the secreted protein level with RosiIG treatment.
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Fig. 2 Regulated canonical pathways by rosiglitazone. Microarray data analysed by Ingenuity Pathway Analysis. Blank bars, with low insulin/
glucose; filled bars, with high insulin/glucose. Bold line, threshold
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Table 2 Effect of rosiglitazone on the expression of genes encoding adipocyte-secreted proteins
Function Gene symbol Gene
ID
Name Rosi/Basal RosiIG/IG
Fold-
change
p value Fold-
change
p value
Lipid
metabolism
Adn 11537 Complement factor D (adipsin) −3.55 0.000 −4.23 0.000
C3 12266 Complement component 3 −2.25 0.000 −2.68 0.001
Lpl 16956 Lipoprotein lipase 1.12 0.166 −1.02 0.627
Apoe 11816 Apolipoprotein E 1.34 0.026 1.18 0.145
Insulin
sensitivity
Retn 57264 Resistin −3.07 0.000 −3.17 0.001
Igf1 16000 Insulin-like growth factor 1 −1.55 0.012 −1.58 0.001
Pbef1 59027 Pre-B-cell colony-enhancing factor 1 −1.24 0.050 −1.28 0.085
Adipoq 11450 Adiponectin −1.09 0.462 −1.25 0.108
Inflammation Hp 15439 Haptoglobin −2.93 0.000 −4.42 0.000
Ptx3 19288 Pentaxin-related gene −1.68 0.001 −1.58 0.000
Tgfb3 21809 Transforming growth factor, beta 3 −1.58 0.008 −1.44 0.056
B2m 12010 Beta-2 microglobulin −1.54 0.018 −1.64 0.006
Ccl2 20296 Chemokine (C-C motif) ligand 2 (previously known as
monocyte chemoattractant protein-1)
−1.54 0.012 −1.48 0.023
Saa3 20210 Serum amyloid A 3 −1.49 0.047 −1.38 0.001
Cxcl12 20315 Chemokine (C-X-C motif) ligand 12 −1.45 0.006 −1.42 0.046
Il6ra 16194 Interleukin 6 receptor, alpha −1.16 0.128 −1.15 0.037
Tgfb1 21803 Transforming growth factor, beta 1 −1.15 0.163 1.02 0.914
Tgfb2 21808 Transforming growth factor, beta 2 −1.15 0.306 −1.07 0.584
Il18 16173 Interleukin 18 −1.15 0.224 −1.01 0.937
D17Wsu104e 28106 DNA segment, Chr 17, Wayne State University 104,
expressed (previously known as IL25)
−1.03 0.794 −1.16 0.088
Lgals1 16852 Lectin, galactose binding, soluble 1 1.05 0.774 1.08 0.590
Lcn2 16819 Lipocalin 2 1.11 0.228 1.20 0.179
Mif 17319 Macrophage migration inhibitory factor 1.18 0.076 1.17 0.137
Vascular
function
Adm 11535 Adrenomedullin −1.41 0.003 −1.50 0.000
Agt 11606 Angiotensinogen −1.22 0.161 −1.15 0.150
Serpinf1 20317 Serine (or cysteine) peptidase inhibitor, clade F, member 1
(previously known as pigment epithelium derived factor)
−1.15 0.237 −1.25 0.187
Vegfa 22339 Vascular endothelial growth factor A −1.03 0.724 −1.08 0.644
Apln 30878 Apelin 1.01 0.969 1.02 0.790
Serpine1 18787 Serine (or cysteine) peptidase inhibitor, clade E, member 1
(previously known as plasminogen activator inhibitor-1)
−1.01 0.897 1.27 0.013
Antioxidant Sod3 20657 Superoxide dismutase 3, extracellular −1.09 0.500 −1.39 0.036
Mt1 17748 Metallothionein 1 −1.11 0.577 −1.12 0.417
Extracellular
matrix
component
Nid2 18074 Nidogen 2 −1.64 0.002 −1.96 0.003
Sparc 20692 Secreted acidic cysteine rich glycoprotein −1.63 0.000 −1.56 0.000
Col5a2 12832 Procollagen, type V, alpha 2 −1.62 0.000 −1.62 0.003
Col5a1 12831 Procollagen, type V, alpha 1 −1.59 0.003 −1.48 0.013
Col1a2 12843 Procollagen, type I, alpha 2 −1.64 0.020 −1.40 0.002
Col1a1 12842 Procollagen, type I, alpha 1 −1.60 0.065 −1.38 0.020
Col3a1 12825 Procollagen, type III, alpha 1 −1.52 0.024 −1.59 0.002
Col4a5 12830 Procollagen, type IV, alpha 5 −1.44 0.034 −1.37 0.019
Col6a2 12834 Procollagen, type VI, alpha 2 −1.32 0.011 −1.19 0.108
Col6a1 12833 Procollagen, type VI, alpha 1 −1.31 0.117 1.05 0.740
Col5a3 53867 Procollagen, type V, alpha 3 −1.20 0.046 −1.29 0.076
Col4a1 12826 Procollagen, type IV, alpha 1 −1.16 0.114 −1.16 0.069
Col4a2 12827 Procollagen, type IV, alpha 2 −1.16 0.153 −1.29 0.003
Nid1 18073 Nidogen 1 −1.04 0.723 1.04 0.767
Col6a3 12835 Procollagen, type VI, alpha 3 −1.03 0.690 −1.01 0.960
Extracellular
matrix
processing
Mmp3 17392 Matrix metalloproteinase 3 −2.01 0.003 −2.02 0.013
Lox 16948 Lysyl oxidase −1.87 0.005 −2.17 0.002
Timp2 21858 Tissue inhibitor of metalloproteinase 2 −1.81 0.002 −1.92 0.000
Mmp2 17390 Matrix metalloproteinase 2 −1.44 0.054 −1.30 0.100
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However, this decrease at the protein level was less
prominent with Rosi treatment (Fig. 5). The secretion of
adiponectin was also analysed by western blotting. A slight
increase with rosiglitazone was detected (Fig. 6), although
there was no change at the gene expression level.
General confirmation of the microarray data by quantita-
tive real-time RT-PCR analysis To confirm our microarray
data, we checked the expression of 22 genes that encode
secreted proteins or are related to lipid metabolism, by Q-
PCR, using Rps15 as reference. Rps15 was chosen because
of its constant expression behaviour on the arrays. A gene
was selected as target gene because either itself or its family
member showed changed expression based on microarray
data. The comparison showed a strong correlation between
array data and Q-PCR data (ESM Fig. 1), with Pearson
correlation coefficients of 0.987 and 0.986 for Rosi/basal
and RosiIG/IG, respectively.
The effect of rosiglitazone on lipolysis We assessed the
glycerol level in the culture medium as a measure of the
lipolysis of adipocytes. RosiIG treatment significantly
Table 2 (continued)
Function Gene symbol Gene
ID
Name Rosi/Basal RosiIG/IG
Fold-
change
p value Fold-
change
p value
Timp1 21857 Tissue inhibitor of metalloproteinase 1 −1.32 0.095 −1.30 0.055
Pcolce 18542 Procollagen C-endopeptidase enhancer protein −1.31 0.029 −1.48 0.002
Mmp19 58223 Matrix metalloproteinase 19 −1.01 0.848 −1.08 0.347
Mmp11 17385 Matrix metalloproteinase 11 1.05 0.860 −1.12 0.413
Timp4 110595 Tissue inhibitor of metalloproteinase 4 1.06 0.672 1.25 0.055
Miscellaneous Gal 14419 Galanin −3.04 0.000 −2.89 0.000
Gsn 227753 Gelsolin −1.63 0.000 −1.52 0.000
Ppic 19038 Peptidylprolyl isomerase C −1.27 0.049 −1.38 0.001
Mean value of microarray data (n=5)
Rosi/basal: the effect with low insulin/glucose; RosiIG/IG: the effect with high insulin/glucose
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Fig. 3 Regulation pattern by
rosiglitazone of genes encoding
extracellular proteins and of
genes encoding intracellular
proteins or proteins of unknown
location. a, c: extracellular pat-
tern; b, d: intracellular pattern.
a, b: rosiglitazone with low
insulin/glucose; c, d: rosiglita-
zone with high insulin/glucose
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increased the release of glycerol from 3T3-L1 mature
adipocytes, whereas glycerol release was significantly
decreased by Rosi treatment (Fig. 7).
Discussion
As a PPARG agonist, rosiglitazone stimulates adipogenesis,
which is accompanied by an increasing lipid content of the
differentiating cells. However, our results showed that
rosiglitazone does not induce an increase of the lipid
content, but decreases it in mature adipocytes at high
insulin/glucose level. The pathway analysis based on
transcriptome data points out that an altered energy
metabolism may underlie this phenomenon.
Although the level of insulin/glucose has some influ-
ence, the effect of rosiglitazone on the transcriptome was
clearly dominant. The most significantly regulated path-
ways by rosiglitazone in 3T3-L1 adipocytes were fatty acid
oxidation, the TCA cycle and oxidative phosphorylation.
Besides an upregulation of fatty acid catabolism pathways,
Fig. 5 The effect of rosiglitazone on the secretion of adipsin as
measured by 2D gel analysis. A section of one representative 2D gel
image is shown for an individual adipsin spot (squares) from (a) low
glucose and insulin control condition (Basal), (b) rosiglitazone with
low insulin and glucose condition (Rosi), (c) high glucose and insulin
control condition (IG) and (d) rosiglitazone with high insulin and
glucose condition (RosiIG). e Total quantity of adipsin in the culture
medium of 3T3-L1 adipocytes expressed in arbitrary units (AU)
Fig. 4 The effect of rosiglitazone on the secretion of complement C3
as measured by 1D gel analysis. The marked bands (arrows) were
identified as C3. One representative image is shown. A sample treated
by Brefeldin A (+BFA) was used to verify secretion
Fig. 6 The effect of rosiglitazone on the secretion of adiponectin as
measured by western blotting. Data are expressed as mean ± SD (n=3)
and one representative western blot image is shown. *p<0.05
compared with Basal condition (t test); **p<0.01 compared with IG
condition (t test). Basal, low glucose and insulin control condition;
Rosi, rosiglitazone with low insulin and glucose condition; IG, high
glucose and insulin control condition; RosiIG, rosiglitazone with high
insulin and glucose condition
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Fig. 7 The effect of rosiglitazone on the culture medium glycerol
levels. Data are expressed as mean±SD (n=3). *p<0.05 compared
with IG condition (t test); **p<0.01 compared with Basal condition
(t test). Basal, low glucose and insulin control condition; Rosi,
rosiglitazone with low insulin and glucose condition; IG, high glucose
and insulin control condition; RosiIG, rosiglitazone with high insulin
and glucose condition
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our data indicate that rosiglitazone encourages adipocytes
to utilise fatty acids for energy production and spares
glucose and amino acids by enhancing glycogen synthesis
and inhibiting amino acid catabolism pathways. This is in
line with the upregulation of Ucp2 and the downregulation
of Scd1 expression. The increase in the level of UCP2 is
correlated with a shift in substrate utilisation in favour of
lipids as the dominant metabolic fuel [28]. SCD1 is
involved in fatty acid synthesis, but it has also been shown
that SCD1 deficiency activates metabolic pathways that
promote beta-oxidation and decrease lipogenesis [29].
Our conclusions regarding energy metabolism are
consistent with recent studies. Mitochondrial changes have
been shown in response to TZD treatment in 3T3-L1
adipocytes [30], human adipocytes in vitro [31] and mouse
adipocytes in vivo [12]. These studies show that TZDs,
including rosiglitazone, upregulate fatty acid oxidation by
increasing mitochondrial protein and gene expression, but
not in a trans-differentiation manner [12, 30]. This has been
confirmed by direct measurement of labelled palmitic acid
oxidation [12] or indirect calorimetric calculation [32]. We
also found that among the genes involved in protein
biosynthesis, more than 80% of those upregulated by
rosiglitazone were genes encoding mitochondrial ribosomal
proteins. This is consistent with an increase of mitochon-
drial biogenesis and remodelling [12]. We speculate that the
maintenance of increased mitochondrial mass and function
utilises (part of) the energy that the cell no longer needs for
lipid synthesis under rosiglitazone treatment.
A decrease in lipogenesis pathways accompanies the
increased fatty acid catabolism pathways caused by
rosiglitazone in mature adipocytes, as shown by decreased
expression of genes encoding triacylglycerol synthesis
enzymes and the genes encoding lipase. The downregula-
tion of Fasn by TZD has also been observed in brown
adipocytes [33]. Caveolin-1 (CAV1) is an important protein
for efficient lipid droplet formation [34]. The downregula-
tion of its gene expression supports a decrease of lipid
accumulation. The upregulation of adipocyte differentiation
related protein gene (Adfp), which encodes a lipid droplet-
associated protein, seems to conflict with the decreased
lipogenesis observed by us (Table 1). However, in mature
3T3-L1 adipocytes, ADFP is spatially associated with lipid
droplets subjected to lipolysis and is suggested to play a
role in lipolysis [35]. Furthermore, the protein level of
ADFP in mature adipocytes is not determined by the
mRNA expression, but by the amount of micro-lipid
droplets [35]. Therefore the increase in Adfp expression
might also be interpreted as being in agreement with
upregulated lipolysis.
The pentose phosphate pathway provides NADPH to be
used in reductive biosynthesis, including fatty acid biosyn-
thesis [36]. Rosiglitazone enhances the pentose phosphate
pathway, but inhibits fatty acid biosynthesis, while stimu-
lating other NADPH-dependent pathways, such as gluta-
thione detoxification, cholesterol and steroid biosynthesis,
and prostaglandin metabolism (carbonyl reductase 3). The
excess of NADPH may be a driving force behind the
upregulation of these pathways by rosiglitazone.
The present study indicates that in mature 3T3-L1
adipocytes rosiglitazone enhances fatty acid catabolism,
increases lipolysis and reduces lipogenesis pathways. This
may lead to a net decrease of lipid content of the cells.
Indeed, we observed increased lipolysis expressed in terms
of an increased glycerol level in the medium and a
decreased lipid content of the cells under RosiIG treatment.
This is in line with the increased lipolysis effected by
rosiglitazone in a recent study on rat white adipose tissue
[37]. We did not observe increased lipolysis under Rosi
treatment, where in fact the glycerol level was decreased
rather than increased. The difference implies that the
insulin/glucose level alters the effect of rosiglitazone. It is
likely that at low insulin/glucose level, the ‘starved’
adipocytes use glycerol as an energy source, rather than
releasing it into the medium. However, it should be noted
that low insulin/glucose is not a realistic situation in vivo
when rosiglitazone is administered. The decreased lipid
content is consistent with the physiological effects of TZDs
in both animal models [10, 38] and in humans [9], where
TZDs increase the number of small adipocytes. In adipose
tissue treated with TZDs, mature adipocytes can become
smaller by actively burning fat, in parallel to the emerging
of small immature adipocytes due to preadipocyte differ-
entiation. With rosiglitazone, mature adipocytes take fatty
acids for burning rather than for storage. This still fits the
‘fatty acid steal’ hypothesis [1] and can explain part of the
glucose-lowering effects of rosiglitazone.
Rosiglitazone affects the function of mature adipocytes not
only with regard to fat metabolism, but also with regard to
adipokine secretion. Despite the limitations of the present
study, namely that a mid-size array was used and that the
expression changes of several genes could not be detected due
to sensitivity, our data at both the mRNA level and the protein
level confirmed that rosiglitazone represses adipokine expres-
sion, except adiponectin and Apoe. Since the majority of
adipokines are negatively correlated with insulin sensitivity
[39], the general repression may correct the disturbance of
insulin sensitivity caused by obesity. Furthermore, our
transcriptome analysis suggests that rosiglitazone induces a
general decrease in expression of genes encoding secreted
proteins. This implies a general mechanism, in which energy
redistribution might be involved.
We observed that repression at the secretion level was
less significant than at the gene expression level. One
explanation is that the effect on protein lags behind the
effect on mRNA. Another reason might be the influence of
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insulin. We have recently studied the role of insulin in 3T3-
L1 adipocyte secretion [19]. We observed that at a low
insulin level, the secretion of proteins is already suppressed.
Consequently, the inhibitory effect of rosiglitazone on
secretion is less prominent in the low insulin condition.
In contrast to most adipokines, adiponectin is reversely
correlated with obesity, and its circulating level is upregulated
by TZDs [40]. A functional PPAR-responsive element
(PPRE) in the adiponectin promoter could be the reason for
the stimulation [41]. We observed an upregulation only at the
secretion level, but not at gene expression level. This is in line
with the conclusion from another study, that although plasma
levels of adiponectin were upregulated by TZDs, there was
no significant effect on adiponectin gene expression [16].
Rosiglitazone is a potent PPARG agonist. It seems
logical to assume that all these effects are mediated through
regulation of PPARG. Indeed, we observed that rosiglita-
zone induced a significant decrease of Pparg expression in
mature 3T3-L1 adipocytes. This is in contrast to an
overwhelming increase during adipogenesis, but it is in
line with several reports [42–44]. With respect to PPARG
downstream effects, we found here that two PPRE-bearing
genes, Cav1 and Scd1, were downregulated, and two other
genes, adiponectin and lipoprotein lipase, remained un-
changed, while most PPRE-bearing genes [45], such as
CD36 antigen, fatty acid binding protein 4, adipocyte and
acyl-coenzyme A oxidase 1, palmitoyl, were upregulated
by rosiglitazone (Tables 1 and 2). The effect of TZDs on
Scd1 in mature adipocytes is opposite to that in preadipo-
cytes [46], and the effect on Cav1 is in contrast to the
reports in other cell types [47, 48]. It has been known that
PPARG acts with different transcriptional partners, co-
repressors and/or co-activators as a complex, to activate or
repress the expression of target genes [49, 50]. Possibly, the
PPARG complex is modulated by rosiglitazone in mature
adipocytes in a manner that is different from that occurring
in preadipocytes and other cell types.
In conclusion, we have shown that rosiglitazone, in
contrast to the stimulation of adipogenesis in preadipocytes,
reduces adiposity of mature adipocytes by increasing fatty
acid catabolism pathways. In addition, rosiglitazone
represses the expression and secretion of adipokines of
mature adipocytes. Our findings suggest that the change of
adiposity as seen in vivo [13] may reflect a shift in balance
between the effects of TZDs on preadipocytes and those on
mature adipocytes, while the changes in circulating adipo-
kine levels primarily result from an effect on mature
adipocytes. These aspects all contribute to the therapeutic
effects of TZDs.
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